Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from JNJ

Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?

Johnson & Johnson had more good than bad; investors should look at the entire report in context before deciding if JNJ stock is a good fit for their portfolios

MarketBeat

Earnings Preview: What to Expect From Johnson & Johnson's Report

Johnson & Johnson is all set to release its fiscal first-quarter earnings this month, and analysts project a single-digit profit decline.

Barchart

Stock Market Today: Stocks Are Mixed Before Liberation Day

Markets are getting into the freewheeling rhythm of a second Trump administration.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Dividend Stocks to Buy for a Safe Haven in This Volatile Market

The consistency in their dividend payments makes them dependable stocks in a volatile market.

Barchart

Resilient Investing: 3 Stocks Built to Weather Market Volatility

Resilient companies with strong financials and diverse revenue in healthcare, technology, and essential services can offer stability in volatile markets.

MarketBeat

Is Johnson & Johnson Stock Underperforming the Dow?

Despite Johnson & Johnson’s underperformance relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

3 Dividend-Paying Stocks Bucking the Market’s Trend

Despite a relentless market-wide selloff on Friday, Coca-Cola, Johnson & Johnson, and McDonald’s showed notable strength, defying the broader downtrend.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

3 "Forever Stocks" You Can Buy and Hold for Decades

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in the economic and geopolitical spheres. In this volatile environment, investors may find value in fundamentally stable stocks like Microsoft (MSFT), Alphabet (GOOGL), and Johnson & Johnson (JNJ). Continue to read….

StockNews.com

3 Defensive Stocks to Buy Before the Next Market Crash

Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a market downturn manifests. Thus, fundamentally stable defensive stocks Walmart (WMT), UnitedHealth Group (UNH), and Johnson & Johnson (JNJ) might be ideal buys for defensive investing. Read on….

StockNews.com

3 Dividend Aristocrats With Consistent Payouts

Investing in dividend aristocrats can form the cornerstone of a reliable investment strategy, owing to their qualities like consistent payouts, recession-proof, and risk protection. So, it could be wise to invest in dividend aristocrat stocks Johnson & Johnson (JNJ), PepsiCo (PEP), and Target (TGT) for substantial gains. Keep reading….

StockNews.com

Johnson & Johnson Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Johnson & Johnson's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Barchart

3 Dividend Growth Stocks Perfect for Long-Term Investors

Dividend growth stocks offer a balance of stability and compounding returns, and here are three standout companies with strong financials, consistent dividend increases, and long-term growth potential: Johnson & Johnson (JNJ), PepsiCo (PEP), and Target (TGT). Read on.

StockNews.com

2 Dividend Kings You Should Snap Up Immediately

Recent earnings from these dividend-paying companies reflects their stability.

Barchart

Abbott Laboratories Will Outperform Healthcare Stocks in 2025

Johnson & Johnson and Abbott Laboratories offer substantial opportunities for investors, but one is a better buy for total returns in 2025 and 2026.

MarketBeat

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

MarketBeat Week in Review – 01/13 - 01/17

The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally

MarketBeat

Is Johnson & Johnson Stock Set to Reward Long-Term Holders?

JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive

StockNews.com

3 Pharmaceutical Stocks Addressing Global Health Challenges

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to pioneering global healthcare solutions. Hence, investing in established pharmaceutical stocks, Pfizer (PFE), Johnson & Johnson (JNJ), and Merck & Co. (MRK) presents a compelling opportunity to capitalize for the long term. Read more.

StockNews.com

3 Blue-Chip Stocks with Strong Buy Ratings from Analysts

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability and long-term growth potential. Thus, one could consider adding these three fundamentally sound blue-chip stocks, AbbVie (ABBV), Merck & Co. (MRK), and Johnson & Johnson (JNJ), with Strong Buy ratings from…

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Top 3 Discounted Dividend Stocks for 2025 That Could Skyrocket Your Portfolio

These three companies are leaders in their field, have a long history of increasing their dividends, and the stocks trade at a discount.

StockNews.com

3 Dividend Aristocrats Every Investor Should Own

Dividend Aristocrats are a shield during market turbulence and a key to diversified growth. Therefore, investors looking for stability and dependable income might consider adding fundamentally stable stocks Johnson & Johnson (JNJ), PepsiCo (PEP), and Kimberly-Clark (KMB). Continue reading….

Barchart

Johnson & Johnson's Quarterly Earnings Preview: What You Need to Know

Johnson & Johnson is poised to release its fiscal fourth-quarter earnings this month, and analysts project a double-digit profit decline.

Barchart

Bearish Screener Results: Bear Call Spread Opportunities for December 19th

Let’s take a look at Barchart’s Bear Call Spread Screener for December 19th:

StockNews.com

3 Healthcare Innovators Revolutionizing Patient Care

The healthcare sector is transforming with the adoption of digital technologies, improved productivity, and increasing R&D efforts. Thus, investors could consider quality healthcare innovator stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and Bristol-Myers Squibb (BMY) as portfolio additions for potential gains. Continue reading.

StockNews.com

3 Healthcare ETFs for a Balanced Investment Approach

For investors seeking a balanced approach, healthcare ETFs offer a combination of stability and growth potential. Therefore, it might be wise to consider Fidelity MSCI Health Care Index ETF (FHLC), iShares U.S. Healthcare ETF (IYH), and Vanguard Health Care Index Fund ETF Shares (VHT) for a balanced approach. Keep reading….

Barchart

Is Johnson & Johnson Stock Underperforming the Nasdaq?

Johnson & Johnson has underperformed the Nasdaq over the past year, but analysts are moderately optimistic about the stock’s prospects.

1 2 3 4 5

People

Gabriel OsorioMazilli

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.